Jump to content

Search the Community

Showing results for tags 'lutetium'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 15 results

  1. MOVEMBER funding will assist Professor Hofman to continue research into Prostate Cancer treatment with Lutetium177. Click https://tinyurl.com/y42kk887 to contribute.Every little bit helps - this is an opportunity to show your support. Tax deductible recieipt - issued when you make your contribution or emailed to you.
  2. Barree

    THERANOSTICS

    THERA-NOSTICS Targeted Theraputic LU177- PSMA -617 DIAGNOSTIC COMPANION GA68-PSMA 11 - Pet/CT PSMA -Many prostate cancer cells have a protein on the surface called PS MA (prostate specific membrane antigen). PSMA 6I7 Ligand is a small peptide (molecule ) with a high binding affinity for PSMA. When injected into the bloodstream it looks for the PSMA exuded on the surface of the prostate cancer cells and bonds to it. This ligand not only bonds to PSMA – it also bonds to Lutetium 177 and Gallium 68 (Ga 68). Gallium 68 is a radioactive isotope. From the time it is made radioactive in the hospital laboratory, it only has a half life of 68 minutes. Lutetium177 is also a radioactive isotope which when made radioactive has a half life of 6.64 days. To determine if you are suitable for Lutetium treatment Firstly a Gallium 68 scan is done Gallium 68 is mixed with the PSMA 11 Ligand, this blend is then injected into the bloodstream. The mixture circulating through the bloodstream is attracted to the protein and starts to build up on the surface of the cancer cel ls (in much the same way as iron filings are attracted to a magnet). If there is no PSMA on the cancer cells – you are NOT considered to be PSMA Avid - the Ligand /Gallium 68 blend will just keep circulating and without any PSMA to adhere to, it will be passed in your urine. When the scan is done – there will be nothing to see – so if you are given a dose of Lutetium 177 / ligand blend it too will do nothing, i t will just pass through the bladder and be excreted with your urine. As the Lutetium177/ Ligand blend will have no PSMA to build up on, you will NOT be considered suitable for treatment with Lutetium177. If you are PSMA avid The Ligand /Gallium 68 blend wi ll keep circulating and be attracted to the protein on the surface of the cancer cells and continue to build up on the surface. This will show up on the scan so the location of the PSMA avid cancer cells can be seen. In this case you maybe suitable for treatment with Lutetium177 but suitability still depends on the results of an FDG scan. Secondly a F18 FDG (Glucose ) scan is done If there is no PSMA on the surface of the cancer cells, the Ga68 scan will show nothing but there could still be cancer present – cancer which is not showing up. This is why it is important to have a F18 FDG (Glucose ) scan. This scan can show cancer which does not exude PSMA and in this case, treatments other than Lutetium 177 would have to be considered. When the two scans do not show prostate cancer in the same position, the scans are considered to be discordant - in which case you are not considered to be a suitable candidate for treatment with Lutetium177 - it just won’t work. When you receive a Lutetium177 injection — it starts circulating through the bloodstream, building up on the protein on the surface of the prostate cancer cells and starts killing the cells beneath the protein. The radiation from this (Lu-PSMA) beta mixture only penetrates about 1mm ,so it will not damage the surrounding non-cancerous tissue. It keeps working flat out for approx 7 and a bit days, and then slowly ceases working over the next few weeks as the radioactivity of the Lutetium177 decays Further Ga68 Scans will show the results of the Lutetium177 treatment.
  3. An interesting account by Professor Michael Hofman at the Advanced Prostate Cancer Consensus Conference in Basel, Switzerland recently. He speaks of the Lutetium-177 (Lu-177) treatment his team and others have done or are planning: https://www.urotoday.com/video-lectures/apccc-2019-conference/video/1467-players-brightcove-net2019-09-10-14-49-08.html Below the video is a full transcript - all the words Professor Hofman says in the video. Thanks to Nev and Lorraine
  4. The trial is titled "Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for PSMA Negative Disease". These clinical trials are headed by Prof. Michael Hofman and A/Prof. Arun Azad of Peter Mac. Recruiting is expected start early next year.Details of these trials will follow later this year. In essence, Lutetium will be given earlier in the piece, Lutetium will in special circumstances be given prior to robotic surgery, Research will commence into CAR T cell treatment for prostate cancer which is not PSMA avid and cannot currently be treated using Lutetium. A dedicated team of specialist Doctors,Scientists and Clinical Researchers at Peter Mac have just successfully applied to the Movember/ Cancer Australia Prostate Cancer Research Alliance for funding of these new Lutetium trials. (see details by clicking this link to the Peter Mac site) http://tinyurl.com/y36xuwqg This is a world-class proposal from a world-class multi-institutional Australian team. Movember and Cancer Australia will jointly provide $4M in funding to the Alliance. In addition generous financial support for these trials totalling $1.4M will also be provided by Peter Mac Foundation, University of Melbourne, Victoria Cancer Agency, Monash University, Epworth/E.J Whitten Foundation, Peter Mac Research Division. This funding will be used solely for prostate cancer research The grant interview team for this project consisted of Prof. Michael Hofman, A/Prof. Arun Azad, A/Prof. Declan Murphy and yours truly as a consumer representative. Hopefully these trials will provide a quantum leap forward for prostate cancer treatment.
  5. Jim Marshall (not a doctor) said ... The clinical trial testing Lutetium-177 therapy against the existing standard therapy (Cabazitaxel (Jevtana)) is taking its first men. It starts at the Peter MacCallum Cancer Center in Melbourne (PeterMac), and other sites will be progressively added. The Prostate Cancer Foundation of Australia (PCFA), with which we are affiliated, has co-sponsored the trial. Below is the message that Daniel Moore of PCFA sent announcing the start. ... end Jim In July 2017 PCFA and ANZUP launched the first Australian trial of a ground-breaking nuclear medicine treatment (Lutetium – 177 PSMA radionuclide therapy) for men with advanced prostate cancer, the TheraP Trial. Today we are pleased to announce this trial is open at Peter MacCallum Cancer Centre in Melbourne with the additional sites to open in the following months. This is an exciting trial and we are aware that you may have members of your group or the community ask you for further information. It is important to remember this treatment won’t be suitable for all those who have prostate cancer. As such, for further details and advice regarding eligibility, please ask anyone interested to print off the trial and contact details from the Australian and New Zealand Clinical Trials Registry (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=6899&isClinicalTrial=True) and speak with their treating physician. To learn more, please view the information page via ANZUP here: http://www.anzup.org.au/content.aspx?page=lutetiumprostatecancertrial.
  6. Does Lutetium177 increase survival 177Lu-PSMA-617 RLT seems to prolong survival in patients with advanced mCRPC pretreated with chemotherapy, abiraterone and/or enzalutamide. This article appeared today in Health Unlocked. To see the article click on the following link - https://tinyurl.com/y7yolyaf
  7. The Australian New Zealand Urogenital Prostate Cancer trials group (ANZUP) held their conference in Melbourne over the weekend and the last couple of days. Yesterday, ANZUP in conjunction with the PCFA announced a new Lutetium trial. A total of 200 men are to be treated - this trial will be spread across Australia. 100 men will receive Lutetium and 100 men will be treated with something else? Full details are yet to be announced, but are due shortly. As soon as details are released,I will post details. Cheers Barree
  8. Guest

    LuPSMA 177 clinical trial

    Hi fellow advanced members Appreciate if anyone can assist with advice re this topic. I am 72 yo with advanced metatstis bones only.Over the past 7 years have had a radical, Radiation- 36 treatments, Chemotherapy - Doxetaxel, Enzuletimide and the whole time on Lucrine. Yep pretty well tried them all and with a rising PSA, now 47- still low compared to some I am faced with more Chemo -Cabazataxel. I have the opportunity to join the 177 LuPSMA pilot study ( 30 in Australia - no placebo) and will start tests next week to see suitability? Is there any member who is doing this trial or knows anything about it? One side affect ( generally well tolerated) is dry saliva and tear glands which I would like to know about? Any comments most welcome. cheers Roger
  9. There have been a number of previous posts in the forums that explain the new treatment known as lutetium PSMA radionuclide therapy, or LuPSMA. The Journal of Nuclear Medicine has a recent report about a study on the “Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer”. The objective of this study was to analyze the safety and efficacy of lutetium PSMA radionuclide therapy. The study was a multi-centre study conducted in Germany. Initial results indicate that treatment with Lu‑PSMA is safe and seems to have low early side-effect profile. A relevant PSA decline was detected in 70 % of patients. Click here to read the report of this study. Peter MacCallum Cancer Centre is planning a further clinical trial with Lu-PSMA in 2017.
  10. Barree :- Lutetium 177 Treatment - Complete and now behind me . 15.11.2016 Update The final infusion of Lutetium177 was administered mid July 2016. Subsequent scans show quite a few of my bone mets have reduced in size and intensity. Blood tests show a falling PSA but bone pain level has not dropped significantly. PSA at the commencement the trial was 85.6. Blood tests in October show it to be 8.3. It seems that this will be the nadir unless some additional treatment is undertaken. At present the only treatment I am receiving is a 10.8 mgm implant of Zolodex every 3 months. Active surveillance is considered to be the appropriate course of action for the next 3 months, that is until a review is done of a comprehensive series of scans - scheduled for mid January 2017. Results of these scans will determine what ongoing treatment program is most likely to be appropriate. Up until 6 months ago testosterone level has been acceptably low but a test for DHT is overdue. It’s probably time to instigate some tests myself to monitor what’s happening to PSA Testosterone and DHT. Should my PSA level remains where it is at 8.3 my preferred treatment option will be to explore the feasibility of having another Lutetium177 infusion. If this is not considered feasible, advisable or too risky, the scans should provide a reasonable indication as to what I should do next. If an additional Lutetium177 treatment is not practical, maybe some sort of salvage radiation therapy might be possible – something like LDR Brachy. However the practicability of this is totally dependent upon the location of the few remaining hot spots and accessibility. This information should be evident when the next Gallium68 PSMA scan results are reviewed. Another major factor determining ongoing therapy will be examination of original radiation treatment levels and prior treatment locations to ensure that there is no likelihood of creating unwanted problems associated with excessive doses of radiation. Fortunately these records are available and accessible and the original radiation treatment was done on an IMRT machine. Bone Pain I have given some thought to Radium 223 but indications to date are that not a lot of patients have found this to provide much relief. The other things left to investigate are Xevga, Bisphosphonates and specialist pain management. Ever Onward - the next trial treatment is still to be determined.
  11. Update Lutetium177 Trial. Peter Mac - Treatment for advanced metastatic prostate cancer. At the start of the trial in February 2016 my PSA level was 86.5, a week ago my PSA level had dropped to 26.3 Prior to the trial - scans showed I had a lot of bony metastases. Comparison of the gamma scans taken after each of the three prior Lutetium177 infusions showed the bony metastases and tumors are progressively shrinking. An accurate determination of just how effective the treatment has been will be carried out in approximately 10 weeks time using a variety of sophisticated Pet Scans. I will post the results. During the course of the trial I found that my eyes, not unexpectedly became quite dry but eye drops have solved this problem. Unlike many others on the trial, I developed quite a sore throat. It has recently been established that this is an oral Thrush infection. I developed a similar problem when on Enzalutamide. It is not an uncommon problem when being treated with Cancer drugs,(as the immune system is compromised) but this can be treated with an over-the-counter pharmacy line. Not unlike most other treatments for Prostate Cancer there are some side-effects caused by the treatment but nothing of a major nature. I am in touch with some others on the trial and from what they have said,my experience (with the exception of the continuous sore throat ) seems to be reasonably representative.
  12. Several of our members have been participating in a clinical trial of Lutetium (Lu 177) being conducted at the Peter MacCallum Cancer Centre in Melbourne, Click here to read an article published in the Australian Financial Review about this clinical trial of Lutetium. A large randomised trial to test this treatment next year will be conducted in 2017.
  13. Admin

    Encore: Lutetium and Search Box

    I noted quite a bit of interest in the posting by Barree updating his experience on the Lutetium-177 trial. http://tinyurl.com/z3moyc3 I'd just like to remind members that whenever they are interested in more information on a topic, every page on the forums has a search box high on the right hand side: And if you're a bit gamer, each search box has a dropdown to narrow your search (including Members, and Advanced Search). Try it an see. Click on the Go to this Topic button below and have a go.
  14. curro

    LU177

    Hi all curro here ..I was diagnosed with an agressive metitasic prostate cancer in February 2013 at age 52 and still have my prostate..Doctors here said they could do nothing so i hav had several different treatments in Europe over last 4 yrs with great success thus far with lastest of a second trearment of LU177 showing signs of puting this cancer into remission and bone repair ...Does anyone know if i can get this here in australia .???
  15. Xofigo (radium 223) has changed the treatment of prostate cancer metastatic to bone. Xofigo is chemically similar to calcium, so tissues that uptake calcium uptake radium as well. That means principally bone, especially in highly metabolically active sites like bone metastases. Lutetium-177 (Lu-177) is a radioactive substance which scientists have attached to an antibody found on the surface of at least 95 percent of prostate cancer cells and called prostate surface membrane antigen (PSMA). Unlike Xofigo, which only attaches to bone metastases, Lu-177-anti-PSMA attaches to any metastasis — bone, lymph node or visceral. It can potentially treat systemic micrometastases as well. Click on the link to read an interesting article in the New Prostate Cancer Infolink.
×
×
  • Create New...